| VGLL4-TEAD1 promotes vascular smooth muscle cell differentiation from human pluripotent stem cells via TET2. | VGLL4-TEAD1 promotes vascular smooth muscle cell differentiation from human pluripotent stem cells via TET2.
Wang Z, Quan Y, Hu M, Xu Y, Chen Y, Jin P, Ma J, Chen X, Fan J, Fan X, Gong Y, Li M, Wang Y. | 03/14/2023 |
| Biochemical properties of VGLL4 from Homo sapiens and Tgi from Drosophila melanogaster and possible biological implications. | Biochemical properties of VGLL4 from Homo sapiens and Tgi from Drosophila melanogaster and possible biological implications.
Mesrouze Y, Meyerhofer M, Zimmermann C, Fontana P, Erdmann D, Chène P., Free PMC Article | 02/5/2022 |
| The lncRNA MEG3/miR-16-5p/VGLL4 regulatory axis is involved in etoposide-induced senescence of tumor cells. | The lncRNA MEG3/miR-16-5p/VGLL4 regulatory axis is involved in etoposide-induced senescence of tumor cells.
Tao Y, Yue P, Miao Y, Gao S, Wang B, Leng SX, Meng X, Zhang H. | 01/15/2022 |
| HOXB13 suppresses proliferation, migration and invasion, and promotes apoptosis of gastric cancer cells through transcriptional activation of VGLL4 to inhibit the involvement of TEAD4 in the Hippo signaling pathway. | HOXB13 suppresses proliferation, migration and invasion, and promotes apoptosis of gastric cancer cells through transcriptional activation of VGLL4 to inhibit the involvement of TEAD4 in the Hippo signaling pathway.
Geng H, Liu G, Hu J, Li J, Wang D, Zou S, Xu X., Free PMC Article | 01/15/2022 |
| VGLL4 inhibits YAP1/TEAD signaling to suppress the epidermal squamous cell carcinoma cancer phenotype. | VGLL4 inhibits YAP1/TEAD signaling to suppress the epidermal squamous cell carcinoma cancer phenotype.
Mickle M, Adhikary G, Shrestha S, Xu W, Eckert RL., Free PMC Article | 08/21/2021 |
| LINC00641 regulates prostate cancer cell growth and apoptosis via the miR-365a-3p/VGLL4 axis. | LINC00641 regulates prostate cancer cell growth and apoptosis via the miR-365a-3p/VGLL4 axis.
Liu WH, Lu JJ, Yu RK, Zhou L, Yu Q, Li DF, Zhu QH. | 07/3/2021 |
| VGLL4 interacts with STAT3 to function as a tumor suppressor in triple-negative breast cancer | VGLL4 interacts with STAT3 to function as a tumor suppressor in triple-negative breast cancer.
Song H, Luo Q, Deng X, Ji C, Li D, Munankarmy A, Jian W, Zhao J, Fang L., Free PMC Article | 06/20/2020 |
| Identification of VGLL4 as an important regulator of PD-L1 expression and a central role of VGLL4 and YAP in the regulation of tumor immunity. | Loss of VGLL4 suppresses tumor PD-L1 expression and immune evasion.
Wu A, Wu Q, Deng Y, Liu Y, Lu J, Liu L, Li X, Liao C, Zhao B, Song H., Free PMC Article | 01/4/2020 |
| our RNA-seq analyses suggest that while the stimulatory effects of CytoD on osteogenesis are pleiotropic and depend on the biological state of the cell type, a small group of genes including VGLL4 may contribute to MSC commitment toward the bone lineage. | Validation of Osteogenic Properties of Cytochalasin D by High-Resolution RNA-Sequencing in Mesenchymal Stem Cells Derived from Bone Marrow and Adipose Tissues.
Samsonraj RM, Paradise CR, Dudakovic A, Sen B, Nair AA, Dietz AB, Deyle DR, Cool SM, Rubin J, van Wijnen AJ., Free PMC Article | 09/21/2019 |
| Data report that VGLL4 functions as a suppressor of breast tumor (BC) growth and progression. Its low expression correlated with a poor prognosis. Its ectopic expression in BC cell lines reduced cell proliferation, migration, and tumor formation in xenograft mouse model. VGLL4 interacts with TEAD1 via its second TEAD-interacting domain, antagonizing YAP-dependent tumor growth. | VGLL4 Selectively Represses YAP-Dependent Gene Induction and Tumorigenic Phenotypes in Breast Cancer.
Zhang Y, Shen H, Withers HG, Yang N, Denson KE, Mussell AL, Truskinovsky A, Fan Q, Gelman IH, Frangou C, Zhang J., Free PMC Article | 03/2/2019 |
| Hippo pathway transcription factor TEAD4 directly associates with the Wnt pathway transcription factor TCF4 via their DNA-binding domains, forming a complex on target genes. VGLL4 binds to this TEAD4-TCF4 complex to inhibit transactivation of both TCF4 and TEAD4. | VGLL4 targets a TCF4-TEAD4 complex to coregulate Wnt and Hippo signalling in colorectal cancer.
Jiao S, Li C, Hao Q, Miao H, Zhang L, Li L, Zhou Z., Free PMC Article | 12/22/2018 |
| Results identify VGLL4 as a direct target gene of miR-130b in Bladder cancer (BCa) cells. Its suppression is crucial for miR-130b-induced BCa cell proliferation, migration and invasion. | miR-130b promotes bladder cancer cell proliferation, migration and invasion by targeting VGLL4.
Liu X, Kong C, Zhang Z. | 09/1/2018 |
| The Vgll4 is phosphorylated in vitro and in vivo by cyclin-dependent kinase 1 (CDK1) during antimitotic drug-induced mitotic arrest and also in normal mitosis. | Cyclin-dependent kinase 1 (CDK1)-mediated mitotic phosphorylation of the transcriptional co-repressor Vgll4 inhibits its tumor-suppressing activity.
Zeng Y, Stauffer S, Zhou J, Chen X, Chen Y, Dong J., Free PMC Article | 09/30/2017 |
| VGLL4 - novel candidate genes validated in a large case-control sample of schizophrenia. | Expression analysis in a rat psychosis model identifies novel candidate genes validated in a large case-control sample of schizophrenia.
Ingason A, Giegling I, Hartmann AM, Genius J, Konte B, Friedl M, Schizophrenia Working Group of the Psychiatric Genomics Consortium (PGC), Ripke S, Sullivan PF, St Clair D, Collier DA, O'Donovan MC, Mirnics K, Rujescu D., Free PMC Article | 07/16/2016 |
| The expression level of VGLL4 protein was down-regulated in gastric cancer tissues.VGLL4 inhibits epithelial-mesenchymal transition in part through suppressing Wnt-beta-catenin signaling pathway in gastric cancer. | VGLL4 inhibits EMT in part through suppressing Wnt/β-catenin signaling pathway in gastric cancer.
Li H, Wang Z, Zhang W, Qian K, Liao G, Xu W, Zhang S. | 03/19/2016 |
| our study suggested that downregulation of VGLL4 was very important in the progression of ESCC, and restoring the function of VGLL4 might be a promising therapeutic strategy for ESCC. | Downregulation of VGLL4 in the progression of esophageal squamous cell carcinoma.
Jiang W, Yao F, He J, Lv B, Fang W, Zhu W, He G, Chen J, He J. | 06/20/2015 |
| VGLL4 directly competes with YAP in binding to TEADs and executes its growth-inhibitory function through two TDU domains. | VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex.
Zhang W, Gao Y, Li P, Shi Z, Guo T, Li F, Han X, Feng Y, Zheng C, Wang Z, Li F, Chen H, Zhou Z, Zhang L, Ji H., Free PMC Article | 04/25/2015 |
| rs2616551 in VGLL4 was found to be nominally associated with anorexia nervosa. | Characterization of genetic variation in the VGLL4 gene in anorexia nervosa.
Clarke TK, Crist RC, Doyle GA, Weiss AR, Brandt H, Crawford S, Crow S, Fichter MM, Halmi KA, Johnson C, Kaplan AS, La Via M, Mitchell JE, Strober M, Rotondo A, Treasure J, Woodside DB, Keel P, Klump KL, Lilenfeld L, Plotnicov K, Magistretti PJ, Bergen AW, Kaye WH, Schork NJ, Berrettini WH., Free PMC Article | 02/28/2015 |
| This study introduces a novel gain-of-function approach for studying hESC maintenance and presents VGLL4 as a previously undescribed regulator of this process. | Brief report: VGLL4 is a novel regulator of survival in human embryonic stem cells.
Tajonar A, Maehr R, Hu G, Sneddon JB, Rivera-Feliciano J, Cohen DE, Elledge SJ, Melton DA., Free PMC Article | 01/17/2015 |
| Loss of VGLL4 expression is associated with gastric cancer. | A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer.
Jiao S, Wang H, Shi Z, Dong A, Zhang W, Song X, He F, Wang Y, Zhang Z, Wang W, Wang X, Guo T, Li P, Zhao Y, Ji H, Zhang L, Zhou Z. | 04/12/2014 |
| Vgl-4 may play a role in the apoptotic pathways by regulating translocation of IAPs between different cell compartments. | A novel inhibitor of apoptosis protein (IAP)-interacting protein, Vestigial-like (Vgl)-4, counteracts apoptosis-inhibitory function of IAPs by nuclear sequestration.
Jin HS, Park HS, Shin JH, Kim DH, Jun SH, Lee CJ, Lee TH. | 11/26/2011 |
| IRF2BP2 was identifies as a novel VGLL4 partner. | IRF2BP2 is a skeletal and cardiac muscle-enriched ischemia-inducible activator of VEGFA expression.
Teng AC, Kuraitis D, Deeke SA, Ahmadi A, Dugan SG, Cheng BL, Crowson MG, Burgon PG, Suuronen EJ, Chen HH, Stewart AF. | 01/8/2011 |
| Clinical trial of gene-disease association and gene-environment interaction. (HuGE Navigator) | Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score.
Rose JE, Behm FM, Drgon T, Johnson C, Uhl GR., Free PMC Article | 06/30/2010 |
| Observational study of gene-disease association. (HuGE Navigator) | Coeliac disease-associated risk variants in TNFAIP3 and REL implicate altered NF-kappaB signalling.
Trynka G, Zhernakova A, Romanos J, Franke L, Hunt KA, Turner G, Bruinenberg M, Heap GA, Platteel M, Ryan AW, de Kovel C, Holmes GK, Howdle PD, Walters JR, Sanders DS, Mulder CJ, Mearin ML, Verbeek WH, Trimble V, Stevens FM, Kelleher D, Barisani D, Bardella MT, McManus R, van Heel DA, Wijmenga C. | 04/1/2009 |
| Vgl-4 modulates the activity of TEF-1 factors and counteracts alpha1-adrenergic activation of gene expression in cardiac myocytes | Vgl-4, a novel member of the vestigial-like family of transcription cofactors, regulates alpha1-adrenergic activation of gene expression in cardiac myocytes.
Chen HH, Mullett SJ, Stewart AF. | 01/21/2010 |